These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23968674)

  • 1. Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?
    Hughes D; Williams-Jones B
    Healthc Policy; 2013 Aug; 9(1):52-64. PubMed ID: 23968674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
    Rose SL; Highland J; Karafa MT; Joffe S
    JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.
    Kang SY; Bai G; Karas L; Anderson GF
    Am J Public Health; 2019 Apr; 109(4):559-561. PubMed ID: 30789768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.
    Parker L; Fabbri A; Grundy Q; Mintzes B; Bero L
    BMJ; 2019 Dec; 367():l6694. PubMed ID: 31831471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Potential Conflicts of Interest among Otolaryngologic Patient Advocacy Organizations in 2016.
    Kondamuri NS; Rathi VK; Naunheim MR; Sethi RV; Miller AL; Varvares MA
    Otolaryngol Head Neck Surg; 2019 Dec; 161(6):967-969. PubMed ID: 31479391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Content Analysis of Patient Advocacy Organization Policies Addressing Institutional Conflicts of Interest.
    Brems JH; McCoy MS
    AJOB Empir Bioeth; 2019; 10(4):215-221. PubMed ID: 31593523
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations.
    Li DG; Singer S; Mostaghimi A
    JAMA Dermatol; 2019 Apr; 155(4):460-464. PubMed ID: 30698625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase.
    Shnier A; Lexchin J; Romero M; Brown K
    BMC Health Serv Res; 2016 Aug; 16(a):383. PubMed ID: 27528247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.
    Mulinari S; Vilhelmsson A; Rickard E; Ozieranski P
    PLoS One; 2020; 15(6):e0235021. PubMed ID: 32579571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conflicts of interest in research involving human beings.
    Greco D; Diniz NM
    J Int Bioethique; 2008; 19(1-2):143-54, 202-3. PubMed ID: 18664007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing stakeholder opinion on relations between cancer patient groups and pharmaceutical companies in Europe.
    Leto di Priolo S; Fehervary A; Riggins P; Redmond K
    Patient; 2012; 5(2):127-39. PubMed ID: 22299759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncologic Drugs Advisory Committee and conflicts of interest.
    Burki TK
    Lancet Oncol; 2016 Mar; 17(3):e95. PubMed ID: 26877161
    [No Abstract]   [Full Text] [Related]  

  • 13. When patient advocacy organizations meet industry: a novel approach to dealing with financial conflicts of interest.
    Ehrlich O; Wingate L; Heller C; de Melo-Martin I
    BMC Med Ethics; 2019 Dec; 20(1):96. PubMed ID: 31847854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pricing increases for cancer drugs sparks investigation.
    Venkatesan P
    Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
    [No Abstract]   [Full Text] [Related]  

  • 15. Robbing Peter to pay Paul? Financial reimbursement for chemotherapy.
    Arceci RJ
    J Pediatr Hematol Oncol; 2003 Apr; 25(4):277-8. PubMed ID: 12679638
    [No Abstract]   [Full Text] [Related]  

  • 16. Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.
    Lane JD; Friedberg MW; Bennett CL
    JAMA Oncol; 2016 Feb; 2(2):274-6. PubMed ID: 26658959
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis C drug maker puts profit ahead of patients, US Senate report charges.
    McCarthy M
    BMJ; 2015 Dec; 351():h6573. PubMed ID: 26635239
    [No Abstract]   [Full Text] [Related]  

  • 18. The politics of access to expensive drugs: INESSS and the innovative pharmaceutical industry.
    Hughes D
    Healthc Policy; 2012 May; 7(4):35-40. PubMed ID: 23634161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Payer management of oncology gets serious.
    Snyder M; Goldberg L; Ryan T
    Am J Manag Care; 2012 Feb; 18(1 Spec No.):SP6-7. PubMed ID: 22468875
    [No Abstract]   [Full Text] [Related]  

  • 20. Physicians' conflicts of interest.
    Stell LK
    APA Newsl Philos Med; 2003; 3(1):161-4. PubMed ID: 15115011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.